Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study.
Phase of Trial: Phase I/II
Latest Information Update: 27 May 2014
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Acronyms ACCEPT
- 23 Apr 2013 Planned end date changed from 1 Oct 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov.
- 13 Sep 2010 New trial record